Movement Alert｜MEDBOT-B Rises 10.72% in Regular Trading, First-Ever Half-Year Profit with Toumai Overseas Revenue Surging Over 450%

Market Focus07-23

On July 23, MEDBOT-B rose 10.72% in regular trading, trading at 23.9 HKD/share, with turnover of HKD 62.26 million. The surge was driven by the company's positive profit alert released on July 22.

According to the announcement, the company expects net profit of RMB 28 million to RMB 40 million for the six months ended June 30, compared to a net loss of RMB 115 million in the same period last year, marking the company's first-ever half-year profitability. Revenue is expected to grow approximately 200% to 230% year-over-year. The core product Toumai laparoscopic surgical robot expanded significantly in both domestic and overseas markets, with overseas market revenue surging over 450% year-over-year. Additionally, Toumai's remote surgery full-department application has obtained EU CE certification, becoming the world's first approved remote surgical robot. The company has achieved over 300 global commercial orders and completed 200 commercial installations across more than 60 countries and regions.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1146257548?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-23 09:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1146257548","market":"hk","top_or_hot":-1,"title":"Movement Alert｜MEDBOT-B Rises 10.72% in Regular Trading, First-Ever Half-Year Profit with Toumai Overseas Revenue Surging Over 450%","media":"Market Focus","content":"<p><p>On July 23, MEDBOT-B rose 10.72% in regular trading, trading at 23.9 HKD/share, with turnover of HKD 62.26 million. The surge was driven by the company's positive profit alert released on July 22.</p><p>According to the announcement, the company expects net profit of RMB 28 million to RMB 40 million for the six months ended June 30, compared to a net loss of RMB 115 million in the same period last year, marking the company's first-ever half-year profitability. Revenue is expected to grow approximately 200% to 230% year-over-year. The core product Toumai laparoscopic surgical robot expanded significantly in both domestic and overseas markets, with overseas market revenue surging over 450% year-over-year. Additionally, Toumai's remote surgery full-department application has obtained EU CE certification, becoming the world's first approved remote surgical robot. The company has achieved over 300 global commercial orders and completed 200 commercial installations across more than 60 countries and regions.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜MEDBOT-B Rises 10.72% in Regular Trading, First-Ever Half-Year Profit with Toumai Overseas Revenue Surging Over 450%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜MEDBOT-B Rises 10.72% in Regular Trading, First-Ever Half-Year Profit with Toumai Overseas Revenue Surging Over 450%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-23 09:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 23, MEDBOT-B rose 10.72% in regular trading, trading at 23.9 HKD/share, with turnover of HKD 62.26 million. The surge was driven by the company's positive profit alert released on July 22.</p><p>According to the announcement, the company expects net profit of RMB 28 million to RMB 40 million for the six months ended June 30, compared to a net loss of RMB 115 million in the same period last year, marking the company's first-ever half-year profitability. Revenue is expected to grow approximately 200% to 230% year-over-year. The core product Toumai laparoscopic surgical robot expanded significantly in both domestic and overseas markets, with overseas market revenue surging over 450% year-over-year. Additionally, Toumai's remote surgery full-department application has obtained EU CE certification, becoming the world's first approved remote surgical robot. The company has achieved over 300 global commercial orders and completed 200 commercial installations across more than 60 countries and regions.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02252","symbol_name":"微创机器人-B","start_time":0,"source_url":"","article_id":"1146257548","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1146257548","pubTimestamp":1784770374,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 23, MEDBOT-B rose 10.72% in regular trading, trading at 23.9 HKD/share, with turnover of HKD 62.26 million. The surge was driven by the company's positive profit alert released on July...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02252":"微创机器人-B"},"translate_title":"走势警报|MEDBOT-B 常规交易上涨 10.72%，首次实现半年盈利，Toumai Overseas 收入飙升超过 450%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02252":1},"content_text":"On July 23, MEDBOT-B rose 10.72% in regular trading, trading at 23.9 HKD/share, with turnover of HKD 62.26 million. The surge was driven by the company's positive profit alert released on July 22.According to the announcement, the company expects net profit of RMB 28 million to RMB 40 million for the six months ended June 30, compared to a net loss of RMB 115 million in the same period last year, marking the company's first-ever half-year profitability. Revenue is expected to grow approximately 200% to 230% year-over-year. The core product Toumai laparoscopic surgical robot expanded significantly in both domestic and overseas markets, with overseas market revenue surging over 450% year-over-year. Additionally, Toumai's remote surgery full-department application has obtained EU CE certification, becoming the world's first approved remote surgical robot. The company has achieved over 300 global commercial orders and completed 200 commercial installations across more than 60 countries and regions.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1146257548","isCrawlerRequest":true}